Susceptibility testing of Leishmania spp. against amphotericin B and fluconazole using the Sensititre™ YeastOne™ YO9 platform

BACKGROUND: Current drug regimens for cutaneous leishmaniasis (CL) include toxic systemic therapies such as amphotericin B (AB) and pentavalent antimonials. Fluconazole (FZ) is a well-tolerated potential oral alternative for the management CL. To date, few objective data exist to guide clinical deci...

Descripción completa

Detalles Bibliográficos
Autores principales: Kariyawasam, Ruwandi, Challa, Priyanka, Lau, Rachel, Boggild, Andrea K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Technical Advance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615197/
https://www.ncbi.nlm.nih.gov/pubmed/31286895
http://dx.doi.org/10.1186/s12879-019-4237-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615197/
https://www.ncbi.nlm.nih.gov/pubmed/31286895
http://dx.doi.org/10.1186/s12879-019-4237-3

Ejemplares similares